Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alkaloid AD SkopjeXMAE:ALK 100 Debt-to-EBITDA is 1.97 as of Jun. 2026, which is 159% above its 10-year median of 0.76. GuruFocus rates XMAE:ALK with a GF Score™ of 100/100 and a GF Value™ of MKD26,911.45 (Modestly Undervalued). Among 690 Drug Manufacturers companies, Alkaloid AD Skopje ranks better than 55.8% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Alkaloid AD Skopje's Debt-to-EBITDA or its related term are showing as below:
XMAE:ALK'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.6 Med: 0.76 Max: 1.62
Current: 1.62
During the past 13 years, the highest Debt-to-EBITDA Ratio of Alkaloid AD Skopje was 1.62. The lowest was 0.60. And the median was 0.76.
XMAE:ALK's Debt-to-EBITDA is ranked better than 55.8% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.65
vs XMAE:ALK: 1.62
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Alkaloid AD Skopje Debt-to-EBITDA Related Terms
Alkaloid AD Skopje Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Alkaloid AD Skopje's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAE:ALK vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alkaloid AD Skopje's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alkaloid AD Skopje Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alkaloid AD Skopje's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alkaloid AD Skopje's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Alkaloid AD Skopje (XMAE:ALK) has a Debt-to-EBITDA of 1.97 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Alkaloid AD Skopje. This is 159% above median its historical median of 0.76. Over the past decade, Alkaloid AD Skopje's Debt-to-EBITDA has ranged from 0.60 to 1.62. According to the industry distribution chart, Alkaloid AD Skopje ranks #305 out of 690 companies in the Drug Manufacturers industry, placing it in the top 44.2%.
Is Alkaloid AD Skopje's Debt-to-EBITDA too high?
Alkaloid AD Skopje's current Debt-to-EBITDA of 1.97 is 159% above median its 10-year median of 0.76. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 1.62. The Drug Manufacturers industry median Debt-to-EBITDA is 1.65. Alkaloid AD Skopje's value of 1.97 is 19.4% above this industry median. Based on the distribution chart, Alkaloid AD Skopje ranks #305 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Alkaloid AD Skopje has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alkaloid AD Skopje's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alkaloid AD Skopje ranks #305 out of 690 companies for Debt-to-EBITDA. This puts Alkaloid AD Skopje in the upper half of its industry. The industry median Debt-to-EBITDA is 1.65. Alkaloid AD Skopje's value of 1.97 is 19.4% above this benchmark. Historically, Alkaloid AD Skopje's own Debt-to-EBITDA has ranged from 0.60 to 1.62 over the past decade. While the company's 10-year median is 0.76 vs. the industry median of 1.65, Alkaloid AD Skopje has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.65, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alkaloid AD Skopje's current Debt-to-EBITDA of 1.97 is 19.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Alkaloid AD Skopje. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alkaloid AD Skopje's current Debt-to-EBITDA is 1.97, which is 159% above median its own 10-year median of 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkaloid AD Skopje stock overvalued right now?
Based on GuruFocus' analysis, Alkaloid AD Skopje (XMAE:ALK) is currently considered Modestly Undervalued. The stock's GF Value™ is MKD26,911.45, compared to a current price of MKD22,999.00 — trading 14.5% below its estimated fair value. The current Debt-to-EBITDA is 1.97, which is 159% above median its 10-year median of 0.76 and 19.4% above the Drug Manufacturers industry median of 1.65. Alkaloid AD Skopje's overall GF Score™ is 100/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Alkaloid AD Skopje (XMAE:ALK), the current Debt-to-EBITDA is 1.97 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alkaloid AD Skopje (XMAE:ALK) Overvalued in 2026?
Based on GuruFocus' analysis, Alkaloid AD Skopje stock appears to be undervalued.
The current stock price of MKD22,999.00 is trading 14.5% below its estimated GF Value™ of MKD26,911.45.
GuruFocus considers Alkaloid AD Skopje to be Modestly Undervalued.
Key valuation signals for XMAE:ALK:
Debt-to-EBITDA: 1.97 (159% above median its 10-year median of 0.76)
GF Value™: MKD26,911.45 vs. price of MKD22,999.00 (14.5% below fair value)
Industry Position: 19.4% above the Drug Manufacturers median (#305 of 690)
No single metric tells the full story. See the XMAE:ALK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alkaloid AD Skopje is engaged in producing and selling pharmaceutical, chemical and cosmetic products, as well as goods from the herbal origin. Its segments are Pharmaceuticals, Chemicals, Cosmetics and Botanicals. It derives maximum revenue from Pharmaceuticals products segment.
100GF Score
Get the complete analysis for XMAE:ALK
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAE:ALK has been successfully added to your 
